ClinicalTrials.gg
CompletedNCT01257425PAMISUpdated Feb 8, 2019Results posted

Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg

A Phase 2 interventional study of Triptorelin Pamoate (Pamorelin® LA 11.25 mg) in Prostate Cancer, sponsored by Ipsen. Completed at 22 sites in Germany. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-08.

Sponsored by Ipsen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.

Enrollment
17th of 28
109 · median 120
Started
2010
with 1 other
Phase 2
7 of 28
3 open now
Registered
9th of 28
by date
Lead sponsor
9 of 28
Ipsen

Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 17th largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 2, and was the 9th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About triptorelin

triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing triptorelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the pharmacodynamic equivalence of triptorelin pamoate (Pamorelin® LA 11.25 mg), applied either IM or SC, in terms of the area under the curve [AUC1-85day] for serum testosterone in patients with advanced prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically proven prostate cancer, locally advanced or , or rising PSA (prostate-specific antigen) after failed local therapy, and the patient scheduled to receive androgen deprivation therapy
  • Serum testosterone levels ≥ 125 ng/dl (1.25 ng/ml, 1.25 microg/l, 4.3 nmol/l) measured by any laboratory or on site within the previous 6 months or at study start
  • performance index > 70
  • Expected survival ≥ 9 months

Exclusion criteria

Exclusion Criteria:

  • Prior hormonal treatment for prostate cancer including gonadotropin-releasing hormone (GnRH) agonists or antagonists within the last 12 months preceding the study or concomitant treatment with one or more of these substance(s)
  • Any current use or within 6 months prior to treatment start of medications which are known to affect the metabolism and/or secretion of androgenic hormones: ketoconazole, aminoglutethimide, oestrogens and progesterone
  • Patient at risk of spinal cord compression or ureter obstruction
  • Prior hypophysectomy or adrenalectomy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
109 participants (actual)

Study arms

  • Other
    Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.

    Drug: Triptorelin Pamoate (Pamorelin® LA 11.25 mg)

  • Other
    Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.

    Drug: Triptorelin Pamoate (Pamorelin® LA 11.25 mg)

Interventions

  • Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85. Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve of Testosterone Serum Concentration Between D1 and D85 (AUC1-85d).

    Area under the curve (AUC) calculated from serum testosterone concentration taken at intervals between the first administration (Day 1) of the study drug and Day 85 after dosing. From the curve describing serum testosterone concentration levels (ng/mL) over time, the AUC was calculated using numerical integration methods. This value was log-transformed to more closely meet the assumption of the statistical method.

    Time frame: 1, 3, 5, 8, 15, 22, 29, 57, 85 days post-dose

Secondary outcomes

  1. Area Under the Curve of Testosterone Serum Concentration Between D1 and D169 (AUC1-169d)

    Area under the curve calculated from serum testosterone concentration taken at intervals between the first administration (Day 1) of the study drug and Day 169 after dosing. From the curve describing serum testosterone concentration levels (ng/mL) over time, the AUC was calculated using numerical integration methods. This value was log-transformed to more closely meet the assumption of the statistical method.

    Time frame: 1, 3, 5, 8, 15, 22, 29, 57, 85, 87, 113, 141 and 169 days post-dose

  2. Area Under the Curve of Testosterone Serum Concentration Between D85 and D169 (AUC85-169d)

    Area under the curve calculated from serum testosterone concentration taken at intervals between Day 85 and Day 169 after dosing. From the curve describing serum testosterone concentration levels (ng/mL) over time, the AUC was calculated using numerical integration methods. This value was log-transformed to more closely meet the assumption of the statistical method.

    Time frame: 85, 87, 113, 141 and 169 days post-dose

  3. Maximum Concentration of Serum Testosterone [Cmax] - Raw Data

    Cmax was assessed as the maximum testosterone serum concentration between the first administration of the study drug and Day 169.

    Time frame: 1, 3, 5, 8, 15, 22, 29, 57, 85, 87, 113, 141 and 169 days post-dose

  4. Maximum Concentration of Serum Testosterone [Cmax] - Log-transformed Data

    Cmax was assessed as the maximum testosterone serum concentration between the first administration of the study drug and Day 169.

    Time frame: 1, 3, 5, 8, 15, 22, 29, 57, 85, 87, 113, 141 and 169 days post-dose

  5. Time to Castration [Tcast] - Testosterone Level Less Than or Equal to 0.5 ng/mL

    tcast is the number of days between day of first administration of the study drug and the day the testosterone level reaches the limit of castration defined as testosterone level less than or equal to 0.5 ng/mL for the first time. Analysis of tcast was based on the Kaplan-Meier estimator.

    Time frame: 12 weeks

  6. Time to Castration [Tcast] - Testosterone Level Less Than 0.5 ng/mL

    tcast is the number of days between day of first administration of the study drug and the day the testosterone level reaches the limit of castration defined as testosterone level less than 0.5 ng/mL for the first time. Analysis of tcast was based on the Kaplan-Meier estimator.

    Time frame: 12 weeks

07

Results

Posted May 26, 2014

Participant flow

Patients diagnosed with advanced prostate cancer (locally advanced or metastatic, histologically proven) recruited at 23 investigational sites in Germany.

Participant flow — Overall Study
MilestoneTriptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.
Started5251
Completed4645
Not completed66
Withdrew: Lack of efficacy33
Withdrew: Adverse event11
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject01
Withdrew: Death10

Outcome measures

PrimaryArea Under the Curve of Testosterone Serum Concentration Between D1 and D85 (AUC1-85d).

Area under the curve (AUC) calculated from serum testosterone concentration taken at intervals between the first administration (Day 1) of the study drug and Day 85 after dosing. From the curve describing serum testosterone concentration levels (ng/mL) over time, the AUC was calculated using numerical integration methods. This value was log-transformed to more closely meet the assumption of the statistical method.

Time frame:
1, 3, 5, 8, 15, 22, 29, 57, 85 days post-dose
Reported as:
Mean · log(ng*day/mL)
Area Under the Curve of Testosterone Serum Concentration Between D1 and D85 (AUC1-85d).
log(ng*day/mL)Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.
Area Under the Curve of Testosterone Serum Concentration Between D1 and D85 (AUC1-85d).4.24 ± 0.404.23 ± 0.50
Statistical analysis
  • Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. vs Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. · ANCOVA · Ratio of auc values: 0.977 · 90% CI 0.88 to 1.08
SecondaryArea Under the Curve of Testosterone Serum Concentration Between D1 and D169 (AUC1-169d)

Area under the curve calculated from serum testosterone concentration taken at intervals between the first administration (Day 1) of the study drug and Day 169 after dosing. From the curve describing serum testosterone concentration levels (ng/mL) over time, the AUC was calculated using numerical integration methods. This value was log-transformed to more closely meet the assumption of the statistical method.

Time frame:
1, 3, 5, 8, 15, 22, 29, 57, 85, 87, 113, 141 and 169 days post-dose
Reported as:
Mean · log(ng*day/mL)
Area Under the Curve of Testosterone Serum Concentration Between D1 and D169 (AUC1-169d)
log(ng*day/mL)Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.
Area Under the Curve of Testosterone Serum Concentration Between D1 and D169 (AUC1-169d)4.49 ± 0.424.52 ± 0.56
Statistical analysis
  • Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. vs Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. · ANCOVA · Ratio of auc values: 0.932 · 90% CI 0.82 to 1.06
SecondaryArea Under the Curve of Testosterone Serum Concentration Between D85 and D169 (AUC85-169d)

Area under the curve calculated from serum testosterone concentration taken at intervals between Day 85 and Day 169 after dosing. From the curve describing serum testosterone concentration levels (ng/mL) over time, the AUC was calculated using numerical integration methods. This value was log-transformed to more closely meet the assumption of the statistical method.

Time frame:
85, 87, 113, 141 and 169 days post-dose
Reported as:
Mean · log(ng*day/mL)
Area Under the Curve of Testosterone Serum Concentration Between D85 and D169 (AUC85-169d)
log(ng*day/mL)Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.
Area Under the Curve of Testosterone Serum Concentration Between D85 and D169 (AUC85-169d)2.80 ± 0.452.88 ± 0.38
Statistical analysis
  • Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. vs Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. · ANCOVA · Ratio of auc values: 0.910 · 90% CI 0.81 to 1.02
SecondaryMaximum Concentration of Serum Testosterone [Cmax] - Raw Data

Cmax was assessed as the maximum testosterone serum concentration between the first administration of the study drug and Day 169.

Time frame:
1, 3, 5, 8, 15, 22, 29, 57, 85, 87, 113, 141 and 169 days post-dose
Reported as:
Mean · ng/mL
Maximum Concentration of Serum Testosterone [Cmax] - Raw Data
ng/mLTriptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.
Maximum Concentration of Serum Testosterone [Cmax] - Raw Data5.74 ± 2.335.50 ± 2.35
SecondaryMaximum Concentration of Serum Testosterone [Cmax] - Log-transformed Data

Cmax was assessed as the maximum testosterone serum concentration between the first administration of the study drug and Day 169.

Time frame:
1, 3, 5, 8, 15, 22, 29, 57, 85, 87, 113, 141 and 169 days post-dose
Reported as:
Mean · log(ng/mL)
Maximum Concentration of Serum Testosterone [Cmax] - Log-transformed Data
log(ng/mL)Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.
Maximum Concentration of Serum Testosterone [Cmax] - Log-transformed Data1.67 ± 0.421.62 ± 0.42
Statistical analysis
  • Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. vs Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. · ANCOVA · p = 0.85 · Mean difference (net): 0.01 · 95% CI -0.09 to 0.11
SecondaryTime to Castration [Tcast] - Testosterone Level Less Than or Equal to 0.5 ng/mL

tcast is the number of days between day of first administration of the study drug and the day the testosterone level reaches the limit of castration defined as testosterone level less than or equal to 0.5 ng/mL for the first time. Analysis of tcast was based on the Kaplan-Meier estimator.

Time frame:
12 weeks
Reported as:
Median · days
Time to Castration [Tcast] - Testosterone Level Less Than or Equal to 0.5 ng/mL
daysTriptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.
Time to Castration [Tcast] - Testosterone Level Less Than or Equal to 0.5 ng/mL22.0 (22.0 to 23.0)22.0 (22.0 to 23.0)
Statistical analysis
  • Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. vs Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. · Log Rank · p = 0.98
SecondaryTime to Castration [Tcast] - Testosterone Level Less Than 0.5 ng/mL

tcast is the number of days between day of first administration of the study drug and the day the testosterone level reaches the limit of castration defined as testosterone level less than 0.5 ng/mL for the first time. Analysis of tcast was based on the Kaplan-Meier estimator.

Time frame:
12 weeks
Reported as:
Median · days
Time to Castration [Tcast] - Testosterone Level Less Than 0.5 ng/mL
daysTriptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.
Time to Castration [Tcast] - Testosterone Level Less Than 0.5 ng/mL22.0 (22.0 to 23.0)22.0 (22.0 to 23.0)
Statistical analysis
  • Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC. vs Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM. · Log Rank · p = 0.84

Adverse events

Collected over Throughout the treatment period: 169 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.—11/52 (21.2%)32/52 (61.5%)
Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.—7/51 (13.7%)25/51 (49%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventTriptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.
Bladder outlet obstructionRenal and urinary disorders0/521/51
HypertensionVascular disorders0/521/51
Inguinal hernia, obstructiveGastrointestinal disorders1/521/51
PlasmacytomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/521/51
PyuriaRenal and urinary disorders0/521/51
Rectal abscessInfections and infestations0/521/51
Renal failure acuteRenal and urinary disorders0/521/51
Subdural haematomaInjury, poisoning and procedural complications0/521/51
Transient ischaemic attackNervous system disorders0/521/51
Urethral stenosisRenal and urinary disorders0/521/51
Most frequent other events
Most frequent other events
EventTriptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.
Hot flushVascular disorders15/5214/51
HyperhidrosisSkin and subcutaneous tissue disorders5/524/51
FatigueGeneral disorders0/523/51
Urinary tract infectionInfections and infestations3/523/51
ArthralgiaMusculoskeletal and connective tissue disorders3/521/51
NocturiaRenal and urinary disorders3/520/51
Sleep disorderPsychiatric disorders3/520/51

Baseline characteristics

Analysed from intent-to-treat (ITT) population comprised of 103 patients (SC: 52 and IM: 51 patients).

Age, Continuous
Age, Continuous(years)Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.Total
Mean73.4 ± 6.773.3 ± 7.073.3 ± 6.8
Age, Customized
Age, Customized(participants)Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.Total
50 to < 60 years224
60 to < 70 years101121
70 to < 80 years303161
80 to < 90 years10717
Sex: Female, Male
Sex: Female, Male(Participants)Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.Total
Female000
Male5251103
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5251103
More than one race000
Unknown or Not Reported000
Karnofsky index (%)
Karnofsky index (%)(participants)Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.Total
100%212748
90%181230
80%131225
Prostate specific antigen (PSA) level
Prostate specific antigen (PSA) level(ng/mL)Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.Total
Mean47.1 ± 174.997.2 ± 368.071.7 ± 286.0
Testosterone serum level
Testosterone serum level(ng/mL)Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.Total
Mean3.23 ± 1.283.12 ± 1.363.18 ± 1.31
Tumour-related pain
Tumour-related pain(cm)Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.Total
Mean0.25 ± 0.580.37 ± 0.990.31 ± 0.81
08

Study locations

22 sites
  • Kreiskrankenhaus, Abteilung Urologie
    Bad Bergzabern, 76887, Germany
  • Praxis für Urologie
    Bad Ems, Germany
  • Praxis für Urologie
    Bamberg, 96047, Germany
  • Praxis für Urologie
    Berlin, Germany
  • Praxis für Urologie
    Braunschweig, Germany
  • Praxis für Urologie
    Cham, Germany
  • Praxis für Urologie
    Chemnitz, Germany
  • Praxis für Urologie
    Dessau, Germany
  • Loretto Krankenhaus, Abteilung Urologie
    Freiburg, 79100, Germany
  • Praxis für Urologie
    Gelsenkirchen, Germany
  • Praxis für Urologie
    Herzberg, Germany
  • Praxis für Urologie
    Lutherstadt Eisleben, Germany
  • Praxis für Urologie
    Marburg, Germany
  • Praxis für Urologie
    Markkleeberg, Germany
  • Praxis für Urologie
    Miltenberg, Germany
  • Praxis für Urologie
    Mülheim, Germany
  • Praxis für Urologie
    München, 81241, Germany
  • Praxis für Urologie
    Neunkirchen, Germany
  • Urologische Klinik
    Neunkirchen, Germany
  • Praxis für Urologie
    Reutlingen, 72764, Germany
  • Praxis für Urologie
    Wesel, Germany
  • Praxis für Urologie
    Wuppertal, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Feb 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2010
First posted
Dec 9, 2010
Start
Dec 2010
Primary completionActual
Feb 2012
CompletionActual
May 2012
Results first posted
May 26, 2014
Last update
Feb 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01257425
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Dec 9, 2010
Start date
Dec 2010
Primary completion
Feb 2012
Completion
May 2012
Results posted
May 26, 2014
Last update
Feb 8, 2019

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion